HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up.

AbstractBACKGROUND:
We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2).
METHODS AND RESULTS:
We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits.
CONCLUSIONS:
Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.
AuthorsAlessia Buglioni, Valentina Cannone, S Jeson Sangaralingham, Denise M Heublein, Christopher G Scott, Kent R Bailey, Richard J Rodeheffer, Riccardo Sarzani, John C Burnett
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 4 Issue 12 (Dec 23 2015) ISSN: 2047-9980 [Electronic] England
PMID26702078 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Chemical References
  • Biomarkers
  • Hypolipidemic Agents
  • Aldosterone
Topics
  • Aged
  • Aldosterone (blood)
  • Biomarkers (blood)
  • Cardiovascular Diseases (blood)
  • Diabetes Mellitus, Type 2 (blood)
  • Echocardiography
  • Female
  • Follow-Up Studies
  • Heart Failure (blood)
  • Humans
  • Hyperlipidemias (blood, drug therapy)
  • Hypertension (blood)
  • Hypolipidemic Agents (therapeutic use)
  • Kidney Diseases (blood)
  • Male
  • Obesity, Abdominal (blood)
  • Predictive Value of Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: